HealthBio, Inc., a biotechnology company developing novel immune-reset therapies for inflammatory disease, today announced the initiation of its multi-center, randomized, double-blind, ...

A new correspondence in Supportive Care in Cancer questions whether the sham design of a randomized trial testing oxycodone ...

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-based personalized immunotherapy for cancer (PIC), today announced the initiation of its Phase 2 ...

Since the interim data cut reported in the accepted manuscript, CAMPX has completed patient enrollment and Last Patient, Last ...

A planned randomized trial in Germany will compare standard care with a 14-week interprofessional outpatient program for 540 ...